<DOC>
	<DOC>NCT00832455</DOC>
	<brief_summary>a study to describe patient and physician satisfaction with montelukast therapy for the control of asthma used either as monotherapy or in combination with inhaled corticosteroids</brief_summary>
	<brief_title>Pediatric ACTION3 (Identify, Treat, Control): Effectiveness of Adding Montelukast in Pediatric Subjects With Uncontrolled Asthma (0476-385)</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Montelukast</mesh_term>
	<criteria>Patient Is Diagnosed With Asthma For At Least 6 Months Patient's Peak Expiratory Flow (PEF) Is 80% Of Predicted Value (Appendix 10) Patient Is Currently Untreated, Or Patient Is A User Of ShortActing 2Agonist On An AsNeeded Basis, Or Patient Is A User Of Ics At Any Dosage Physician And/Or Patient Are Dissatisfied With Current Controller Therapy, Or Patient Is Reluctant To Take Ics Therapy, Or Patient Is Insufficiently Controlled Due To NonAdherence With Current Therapy Through The Preceding 6 Weeks As Per Canadian Guidelines, Patient Is On A Laba Alone (Formoterol (Oxeze), Salmeterol (Serevent)) Or A Combination Product (Advair Or Symbicort) Patient Is Well Controlled, Adherent And Satisfied With Current Controller Therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>